CAH vs GILD: fair value comparison
Cardinal Health, Inc. and Gilead Sciences, Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CAH currently sits closer to the top of our discount ranking. GILD carries the stronger quality grade.
| CAH | GILD | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $234.57 | $143.72 |
| 12-month range | $190.22–$239.35 | $119.79–$150.03 |
| Sector rank | #97 of 113 Healthcare | #102 of 113 Healthcare |
| Quality grade | F | C |
| Leverage | Low | High |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CAH fair value analysis · GILD fair value analysis